Vol. 5 No. 10 (2025)
Reimbursement Reviews

Durvalumab (Imfinzi) and Tremelimumab (Imjudo)

decorative image of the issue cover

Published October 27, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses durvalumab (Imfinzi), 50 mg/mL, concentrate for IV infusion (in combination with tremelimumab [Imjudo], 20 mg/mL, concentrate for IV infusion).
  • Indication: Durvalumab in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic non–small cell lung cancer with no sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase genomic tumour aberrations.